5416W-13 A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold

A Clinical Evaluation of Absorbâ„¢ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

Type of Study
Heart & Vascular - Interventional Cardiology Trials
Short Description
The purpose of this Study is to assess the safety and effectiveness of treating blockages in the coronary (heart) arteries (blood vessels) with an investigational (experimental) device called Absorb™ Bioresorbable Vascular Scaffold (BVS) System (the “Absorb BVS”), compared to a commercially approved metallic stent coated with medication (drug-eluting stent).
 
Status
Open
Principal Investigator
Robert Bersin, MD
Eligibility Notes
Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, post-infarct angina or silent ischemia) suitable for elective PCI. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
 
Contact Name
Stephen Lubatti and Jeremy Gillis, BS
Phone
206-215-6573
Alternate Phone
206-215-2437
Email
stephen.lubatti2@swedish.org
Alternate Email
jeremy.gillis@swedish.org